No

Faculty will review emerging clinical and translational data targeting KRAS and related pathways, including efficacy signals, resistance mechanisms, and safety considerations, in the treatment of pancreatic cancer. They will discuss patient selection, biomarker testing, and how these agents may integrate with existing treatment regimens, providing perspective on the readiness of RAS inhibitors to move from investigational use to routine clinical application. Modest efficacy signals, narrow biomarker applicability, and emerging resistance mechanisms represent real concerns in the discussion of RAS inhibitor use in pancreatic cancer. Faculty will discuss safety concerns, durability of response, and unanswered questions regarding optimal sequencing and combinations to inform learners on why RAS inhibitors remain best positioned within clinical trials rather than routine practice at this time.